In this issue of Blood, Zhang et al describe an exciting new small-molecule antagonist of CXCL12-CXCR4 binding with a potent ability to mobilize hematopoietic stem cells (HSCs). Further clinical development of this new drug,Me6TREN, may have broad applications in stem-cell mobilization for cancer and in regenerative medicine.